The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.
Zacks.com on MSN22h
Biogen Stock Down on Regulatory Update in the EU for Alzheimer's DrugThe EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of ...
Verywell Health on MSN6d
New Maintenance Dosing Option for Alzheimer's Drug Leqembi Offers FlexibilityVerywell Health's content is for informational and educational purposes only. Our website is not intended to be a substitute ...
In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...
Biogen and Eisai said they believe that EC's requests can be addressed with existing information, and that no new safety signals have been identified for Leqembi. The U.S. Food and Drug Administration ...
The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...
Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback